Overview

BoldScience creates multi-channel medical communications programs to help pharmaceutical companies explain complex science to doctors, patients, and other healthcare stakeholders. Its offerings mix content development, brand-building, and strategic outreach to communicate new mechanisms, speed clinical trial recruitment, and differentiate products in the healthcare market. The approach centers on translating intricate scientific concepts into clear, engaging materials delivered across suitable channels to extend publication impact. As part of CO LAB GLOBAL, BoldScience leverages a global network to enable cross-border collaboration and broader resource access, with the goal of helping clients shape standards of care and advance science-driven care.

Simplify's Take

What believers are saying

• Acquired by Amulet-backed Minds + Assembly in November 2024 expands services.
• Grew 700% in first year, securing 20 blue-chip pharma clients.
• Preferred agency for five top-20 pharma with 75+ staff globally.

What critics are saying

• Minds + Assembly merger dilutes medcomms focus, loses clients in 6-12 months.
• FDA scrutiny fines BOLDADVOCACY operations within 12-18 months.
• ICON plc bundles cheaper CRO-comms, erodes clients in 12-24 months.

What makes BOLDSCIENCE unique

• BOLDSCIENCE blends high-science translation with creative digital innovation.
• Offers full-service teams for pharma clients of any scale.
• Launched BOLDADVOCACY division led by Kristin Ludwig in 2024.

Help us improve and share your feedback! Did you find this helpful?

YesNo